Cyclosporine-sparing effects of daclizumab in renal allograft recipients

Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation

“…Our results confirm in part the results of Vincenti, Nashan and Ingle [7,8,24,25], and indicate significantly decreased acute rejection with induction therapies. Although only a secondary outcome, the biopsy-proven rejection rate in the daclizumab group over the 1-year observation period was only 7% while a rate of 26% was observed in the standard therapy group.…”

“…Other groups corroborate that the use of daclizumab not only reduces acute rejection [26], but permits the reduction of steroids [6,27,28] or the reduction or delayed introduction of the CNIs [24,[29][30][31][32][33]. Similarly to our study, lower CsA concentrations in combination with initially high-dose daclizumab were associated with reduced acute rejection, reduced need for biopsy and lower chronic rejection rates.…”

Extended daclizumab monotherapy for rejection‐free survival in non‐adherent adolescent recipients of renal allografts

“…Daclizumab in newer protocols allow sparing of other more toxic immunosuppressive agents reducing the need for calcineurin inhibitors while maintaining the overall efficacy of the regimen, thus increasing the safety margin (less toxicity, fewer adverse effects) of the baseline immunosuppression (3, 27–33). It has an excellent tolerability profile (similar to placebo) with no significant effect on the incidence of infection, malignancy, and cardiovascular risk (34).…”